The addition of tesmilifene to mitoxantrone and prednisone reduces pain and prostate-specific antigen levels in patients with painful, hormone-refractory prostate cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1518, 2005-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Which drug combination for hormone-refractory prostate cancer?

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 667-670

Informa Healthcare

Access to resources Recommend Favorite

Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer

By  

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-05 ,pp. : 915-920

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel: In Hormone-Refractory Metastatic Prostate Cancer

By McKeage Kate   Keam Susan J.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2287-2294

Adis International

Access to resources Recommend Favorite

Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer

By Mahal Brandon A.   Aizer Ayal A.   Efstathiou Jason A.   Nguyen Paul L.  

Cancer, Vol. 122, Iss. 1, 2016-01 ,pp. : 78-83

Blackwell Publishing

Access to resources Recommend Favorite

Docetaxel in Hormone-Refractory Metastatic Prostate Cancer: A Viewpoint by William R. Berry

By Berry William R.  

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2295-2297

Adis International

Access to resources Recommend Favorite